OPO54-LB4a multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL12/23p40, in patients with moderately-severely Crohn’s disease who are naïve or not refractory to anti TNFa: UNITI-2 - Feagan, B; Gsink, C; Lang, Y (United European Gastroenterol J, 2015)
et al.